vs

Side-by-side financial comparison of AerSale Corp (ASLE) and Theravance Biopharma, Inc. (TBPH). Click either name above to swap in a different company.

AerSale Corp is the larger business by last-quarter revenue ($90.9M vs $45.9M, roughly 2.0× Theravance Biopharma, Inc.). Theravance Biopharma, Inc. runs the higher net margin — 133.0% vs 5.9%, a 127.0% gap on every dollar of revenue. On growth, Theravance Biopharma, Inc. posted the faster year-over-year revenue change (144.7% vs -4.0%). Over the past eight quarters, Theravance Biopharma, Inc.'s revenue compounded faster (77.9% CAGR vs 0.2%).

AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.

Theravance Biopharma, Inc. is a global biopharmaceutical enterprise focused on researching, developing and commercializing innovative medicines for patients with serious, unmet medical needs, primarily targeting respiratory and infectious disease segments. It operates core markets across North America and Europe, partnering with global healthcare stakeholders to advance its therapy pipeline and deliver effective, accessible treatment options to underserved patient groups.

ASLE vs TBPH — Head-to-Head

Bigger by revenue
ASLE
ASLE
2.0× larger
ASLE
$90.9M
$45.9M
TBPH
Growing faster (revenue YoY)
TBPH
TBPH
+148.7% gap
TBPH
144.7%
-4.0%
ASLE
Higher net margin
TBPH
TBPH
127.0% more per $
TBPH
133.0%
5.9%
ASLE
Faster 2-yr revenue CAGR
TBPH
TBPH
Annualised
TBPH
77.9%
0.2%
ASLE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASLE
ASLE
TBPH
TBPH
Revenue
$90.9M
$45.9M
Net Profit
$5.4M
$61.0M
Gross Margin
34.1%
Operating Margin
7.8%
43.6%
Net Margin
5.9%
133.0%
Revenue YoY
-4.0%
144.7%
Net Profit YoY
99.7%
493.0%
EPS (diluted)
$0.10
$1.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASLE
ASLE
TBPH
TBPH
Q4 25
$90.9M
$45.9M
Q3 25
$71.2M
$20.0M
Q2 25
$107.4M
$26.2M
Q1 25
$65.8M
$15.4M
Q4 24
$94.7M
$18.8M
Q3 24
$82.7M
$16.9M
Q2 24
$77.1M
$14.3M
Q1 24
$90.5M
$14.5M
Net Profit
ASLE
ASLE
TBPH
TBPH
Q4 25
$5.4M
$61.0M
Q3 25
$-120.0K
$3.6M
Q2 25
$8.6M
$54.8M
Q1 25
$-5.3M
$-13.6M
Q4 24
$2.7M
$-15.5M
Q3 24
$509.0K
$-12.7M
Q2 24
$-3.6M
$-16.5M
Q1 24
$6.3M
$-11.7M
Gross Margin
ASLE
ASLE
TBPH
TBPH
Q4 25
34.1%
Q3 25
30.2%
Q2 25
32.9%
Q1 25
27.3%
Q4 24
31.4%
Q3 24
28.6%
Q2 24
28.2%
Q1 24
31.8%
Operating Margin
ASLE
ASLE
TBPH
TBPH
Q4 25
7.8%
43.6%
Q3 25
4.0%
-32.3%
Q2 25
11.7%
-10.4%
Q1 25
-10.1%
-93.8%
Q4 24
5.2%
-49.1%
Q3 24
2.4%
-64.2%
Q2 24
-2.4%
-110.2%
Q1 24
5.2%
-77.3%
Net Margin
ASLE
ASLE
TBPH
TBPH
Q4 25
5.9%
133.0%
Q3 25
-0.2%
18.1%
Q2 25
8.0%
209.3%
Q1 25
-8.0%
-88.2%
Q4 24
2.9%
-82.8%
Q3 24
0.6%
-75.3%
Q2 24
-4.7%
-115.9%
Q1 24
6.9%
-80.4%
EPS (diluted)
ASLE
ASLE
TBPH
TBPH
Q4 25
$0.10
$1.18
Q3 25
$0.00
$0.07
Q2 25
$0.18
$1.08
Q1 25
$-0.10
$-0.27
Q4 24
$0.05
$-0.31
Q3 24
$0.01
$-0.26
Q2 24
$-0.07
$-0.34
Q1 24
$0.12
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASLE
ASLE
TBPH
TBPH
Cash + ST InvestmentsLiquidity on hand
$4.4M
$167.8M
Total DebtLower is stronger
$1.3M
Stockholders' EquityBook value
$424.4M
$296.7M
Total Assets
$640.5M
$485.6M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASLE
ASLE
TBPH
TBPH
Q4 25
$4.4M
$167.8M
Q3 25
$5.3M
$174.8M
Q2 25
$5.7M
$281.9M
Q1 25
$4.7M
$110.6M
Q4 24
$4.7M
$37.8M
Q3 24
$9.8M
$23.4M
Q2 24
$4.3M
$46.3M
Q1 24
$2.6M
$53.8M
Total Debt
ASLE
ASLE
TBPH
TBPH
Q4 25
$1.3M
Q3 25
$1.5M
Q2 25
$907.0K
Q1 25
$1.1M
Q4 24
$1.2M
Q3 24
$376.0K
Q2 24
$522.0K
Q1 24
$3.5M
Stockholders' Equity
ASLE
ASLE
TBPH
TBPH
Q4 25
$424.4M
$296.7M
Q3 25
$417.1M
$232.7M
Q2 25
$415.9M
$224.8M
Q1 25
$406.5M
$166.0M
Q4 24
$455.6M
$175.5M
Q3 24
$451.5M
$185.7M
Q2 24
$449.8M
$193.7M
Q1 24
$452.0M
$204.9M
Total Assets
ASLE
ASLE
TBPH
TBPH
Q4 25
$640.5M
$485.6M
Q3 25
$646.3M
$415.5M
Q2 25
$646.7M
$426.0M
Q1 25
$646.1M
$343.6M
Q4 24
$604.7M
$354.2M
Q3 24
$601.5M
$356.1M
Q2 24
$598.7M
$362.0M
Q1 24
$571.7M
$371.3M
Debt / Equity
ASLE
ASLE
TBPH
TBPH
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASLE
ASLE
TBPH
TBPH
Operating Cash FlowLast quarter
$11.4M
$-6.1M
Free Cash FlowOCF − Capex
$9.8M
FCF MarginFCF / Revenue
10.8%
Capex IntensityCapex / Revenue
1.7%
Cash ConversionOCF / Net Profit
2.11×
-0.10×
TTM Free Cash FlowTrailing 4 quarters
$-29.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASLE
ASLE
TBPH
TBPH
Q4 25
$11.4M
$-6.1M
Q3 25
$-8.9M
$-6.5M
Q2 25
$19.8M
$208.1M
Q1 25
$-45.2M
$43.0M
Q4 24
$37.5M
$-902.0K
Q3 24
$10.4M
$-5.2M
Q2 24
$-15.3M
$-4.4M
Q1 24
$-21.5M
$-1.0M
Free Cash Flow
ASLE
ASLE
TBPH
TBPH
Q4 25
$9.8M
Q3 25
$-9.8M
Q2 25
$18.6M
Q1 25
$-47.6M
Q4 24
$32.3M
$-1.1M
Q3 24
$8.9M
$-5.2M
Q2 24
$-18.9M
$-4.5M
Q1 24
$-25.0M
$-1.1M
FCF Margin
ASLE
ASLE
TBPH
TBPH
Q4 25
10.8%
Q3 25
-13.8%
Q2 25
17.3%
Q1 25
-72.4%
Q4 24
34.0%
-5.8%
Q3 24
10.7%
-30.9%
Q2 24
-24.6%
-31.2%
Q1 24
-27.7%
-7.7%
Capex Intensity
ASLE
ASLE
TBPH
TBPH
Q4 25
1.7%
Q3 25
1.3%
0.0%
Q2 25
1.1%
Q1 25
3.7%
Q4 24
5.6%
1.0%
Q3 24
1.9%
0.1%
Q2 24
4.7%
0.3%
Q1 24
3.9%
0.6%
Cash Conversion
ASLE
ASLE
TBPH
TBPH
Q4 25
2.11×
-0.10×
Q3 25
-1.80×
Q2 25
2.31×
3.79×
Q1 25
Q4 24
13.89×
Q3 24
20.52×
Q2 24
Q1 24
-3.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASLE
ASLE

Products$57.8M64%
Maintenance$23.2M26%
Leasing Arrangements$9.9M11%

TBPH
TBPH

Segment breakdown not available.

Related Comparisons